$GH

Kalia Kumud sold $652K of GH

Kalia Kumud (Chief Information Officer) sold 5,000 shares of Guardant Health, Inc. (GH) at $130.41 ($0.65M total) on 2026-06-10.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 12, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may slightly influence sentiment, but it does not constitute new operational/regulatory/financial guidance.

02

Market read

A ~$652K insider sale is newly disclosed; traders may monitor for follow-on insider activity but should not treat it as a fundamental catalyst.

03

What to watch

The article doesn’t state whether additional insiders sold/bought around the same time, nor does it provide the insider’s total compensation context or whether other transactions occurred after 2026-06-10.

Relevance 5/10Novelty 8/10Timing: filed 2026-06-12 (covers sale dated 2026-06-10)

Background

SEC Form 4 reports an officer’s direct open-market sale of Guardant Health shares.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health CIO Kalia Kumud filed an open-market sale of 5,000 shares on 2026-06-10 for ~$652K (Form 4).

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades unless follow-on selling accelerates.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not a buy, not tied to a disclosed corporate event, and the article provides no broader fundamental change.

Market effects

No direct sector read-through; this is company-specific insider liquidity/positioning information.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for diversification or tax/comp liquidity; the absence of a 10b5-1 plan in the filing doesn’t automatically imply negative fundamentals.

Key entities

  • Guardant Health, Inc.

    Public company whose insider transaction is disclosed on Form 4.

  • Kalia Kumud

    Chief Information Officer reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.